Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
The use of adjuvant 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; lomustine) to treat incompletely excised canine mast cell tumors (MCTs) has not been evaluated. Medical records of 12 dogs with grade 2 MCT treated with incomplete surgical excision and adjuvant CCNU and prednisone chemotherapy were reviewed. Local recurrence rate, metastasis rate, and survival time were evaluated. None of the dogs developed local recurrence or regional/ distant metastases. Two dogs developed fatal liver failure. The 1- and 2-year progression-free rates of surviving dogs were 100% and 77%, respectively. Postoperative adjuvant CCNU appears to be a useful alternative to radiation therapy for incompletely excised canine cutaneous MCTs.
Hosoya
Kenji
K
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, 601 Vernon L. Tharp Street, Columbus, Ohio 43210, USA.
Kisseberth
William C
WC
Alvarez
Francisco J
FJ
Lara-Garcia
Ana
A
Beamer
Gillian
G
Stromberg
Paul C
PC
Couto
C Guillermo
CG
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000601:surgery; D004285:Dogs; D004359:Drug Therapy, Combination; D005260:Female; D017093:Liver Failure / Q000209:etiology / Q000662:veterinary; D008130:Lomustine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012515:Mast-Cell Sarcoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies; D016019:Survival Analysis
D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D008130:Lomustine; D011241:Prednisone